A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with be...
October 25, 2026
Share
A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
